First Quarter 2018 Investor Presentation
Investor Presentation
First three months of 2018
Slide 69
The GLP-1 segment accounts for 3% of total diabetes care
market value in Region AAMEO
GLP-1 value
in bDKK
Region AAMEO GLP-1 market
VictozaⓇ
exenatide
VictozaⓇ value market share in Region AAMEO
VictozaⓇ
exenatide
▪dulaglutide
lixisenatide
dulaglutide Share of total
lixisenatide diabetes care
GLP-1 value
market share
market
0.6
3%
100%
0.5
CAGR value¹: 25.5%
80%
0.4
- 2%
60%
0.3
40%
0.2
1%
20%
0.1
0.0
0%
0%
Feb
2013
Feb
2018
Feb
2013
1 CAGR for 5-year period
AAMEO: Africa, Asia, the Middle East and Oceania
Source: IQVIA monthly MAT Feb, 2018 value figures (DKK)
changing
diabetes
Source: IQVIA monthly MAT Feb, 2018 value figures (DKK), ), market share does not
add up to 100% due to rounding
.47%
34%
-19%
1%
Feb
2018
novo nordiskView entire presentation